vs
Prime Medicine, Inc.（PRME）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Arcadia Biosciences, Inc.的季度营收约是Prime Medicine, Inc.的1.1倍（$901.0K vs $838.0K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -5498.7%，领先5350.4%），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -61.6%）
Prime Medicine, Inc.是一家总部位于美国马萨诸塞州剑桥的生物科技企业，核心业务是依托先导编辑技术开发新型基因治疗方案，致力于为遗传病等相关疾病探索创新治疗手段，推动前沿基因编辑技术的临床转化与应用。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
PRME vs RKDA — 直观对比
营收规模更大
RKDA
是对方的1.1倍
$838.0K
营收增速更快
RKDA
高出35.8%
-61.6%
净利率更高
RKDA
高出5350.4%
-5498.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $838.0K | $901.0K |
| 净利润 | $-46.1M | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | -5800.5% | -152.8% |
| 净利率 | -5498.7% | -148.3% |
| 营收同比 | -61.6% | -25.8% |
| 净利润同比 | -9.0% | 67.1% |
| 每股收益（稀释后） | $-0.22 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRMERKDA
| Q4 25 | $838.0K | $901.0K | ||
| Q3 25 | $1.2M | $1.3M | ||
| Q2 25 | $1.1M | $1.5M | ||
| Q1 25 | $1.5M | $1.2M | ||
| Q4 24 | $2.2M | $1.2M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | $0 | $1.3M | ||
| Q1 24 | $591.0K | $987.0K |
净利润PRMERKDA
| Q4 25 | $-46.1M | $-1.3M | ||
| Q3 25 | $-50.6M | $856.0K | ||
| Q2 25 | $-52.6M | $-4.5M | ||
| Q1 25 | $-51.9M | $2.6M | ||
| Q4 24 | $-42.3M | $-4.1M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | $-55.3M | $1.1M | ||
| Q1 24 | $-45.8M | $-2.4M |
毛利率PRMERKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率PRMERKDA
| Q4 25 | -5800.5% | -152.8% | ||
| Q3 25 | -4406.0% | -88.5% | ||
| Q2 25 | -4787.2% | -34.4% | ||
| Q1 25 | -3603.3% | 44.2% | ||
| Q4 24 | -2025.7% | -187.7% | ||
| Q3 24 | — | -114.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | -8179.5% | -160.9% |
净利率PRMERKDA
| Q4 25 | -5498.7% | -148.3% | ||
| Q3 25 | -4129.1% | 65.7% | ||
| Q2 25 | -4716.7% | -306.4% | ||
| Q1 25 | -3568.8% | 216.6% | ||
| Q4 24 | -1936.6% | -334.5% | ||
| Q3 24 | — | -104.9% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | -7743.0% | -245.5% |
每股收益（稀释后）PRMERKDA
| Q4 25 | $-0.22 | $-0.97 | ||
| Q3 25 | $-0.32 | $0.62 | ||
| Q2 25 | $-0.41 | $-3.26 | ||
| Q1 25 | $-0.40 | $1.90 | ||
| Q4 24 | $-0.31 | $-2.99 | ||
| Q3 24 | — | $-1.18 | ||
| Q2 24 | $-0.46 | $0.78 | ||
| Q1 24 | $-0.44 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.0M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $120.9M | $4.1M |
| 总资产 | $342.7M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRMERKDA
| Q4 25 | $63.0M | $4.6M | ||
| Q3 25 | $71.4M | $5.9M | ||
| Q2 25 | $53.8M | $4.4M | ||
| Q1 25 | $91.9M | $3.2M | ||
| Q4 24 | $182.5M | $4.2M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | $55.6M | $8.1M | ||
| Q1 24 | $94.2M | $8.5M |
股东权益PRMERKDA
| Q4 25 | $120.9M | $4.1M | ||
| Q3 25 | $161.8M | $5.4M | ||
| Q2 25 | $60.9M | $4.5M | ||
| Q1 25 | $106.9M | $8.9M | ||
| Q4 24 | $153.1M | $6.2M | ||
| Q3 24 | — | $10.3M | ||
| Q2 24 | $196.6M | $11.7M | ||
| Q1 24 | $243.8M | $10.6M |
总资产PRMERKDA
| Q4 25 | $342.7M | $6.5M | ||
| Q3 25 | $385.0M | $8.6M | ||
| Q2 25 | $279.0M | $7.8M | ||
| Q1 25 | $328.2M | $13.0M | ||
| Q4 24 | $297.5M | $13.5M | ||
| Q3 24 | — | $15.2M | ||
| Q2 24 | $259.7M | $17.4M | ||
| Q1 24 | $311.4M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.3M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | $-37.5M | — |
| 自由现金流率自由现金流/营收 | -4480.4% | — |
| 资本支出强度资本支出/营收 | 34.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-167.1M | — |
8季度趋势，按日历期对齐
经营现金流PRMERKDA
| Q4 25 | $-37.3M | $-861.0K | ||
| Q3 25 | $-35.0M | $-257.0K | ||
| Q2 25 | $-41.4M | $-2.0M | ||
| Q1 25 | $-48.9M | $-1.6M | ||
| Q4 24 | $16.2M | $-2.2M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | $-45.5M | $-2.5M | ||
| Q1 24 | $-67.7M | $-3.2M |
自由现金流PRMERKDA
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-35.3M | — | ||
| Q2 25 | $-43.0M | — | ||
| Q1 25 | $-51.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-47.4M | $-2.5M | ||
| Q1 24 | $-70.0M | $-3.2M |
自由现金流率PRMERKDA
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | — | ||
| Q2 25 | -3855.1% | — | ||
| Q1 25 | -3526.8% | — | ||
| Q4 24 | 662.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | -11849.6% | -326.5% |
资本支出强度PRMERKDA
| Q4 25 | 34.6% | 0.0% | ||
| Q3 25 | 20.2% | 0.0% | ||
| Q2 25 | 141.0% | 0.0% | ||
| Q1 25 | 166.6% | 0.0% | ||
| Q4 24 | 82.0% | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | 393.2% | 1.3% |
现金转化率PRMERKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
